PATENT CLAIM ANALYSIS

Application Number: 15994502
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2019-03
Patent Classification: ["514", "183000"]

Abstract:
The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to bisantrene or derivatives, analogs, or prodrugs thereof.

Claim (Index 39):
A composition to improve the efficacy and/or reduce the side effects of suboptimally administered drug therapy comprising a therapeutically effective quantity of a therapeutic agent or modified therapeutic agent, wherein the composition further comprises:\n (a) an additional therapeutic agent; (b) a therapeutic agent subject to chemosensitization; (c) a therapeutic agent subject to chemopotentiation; (d) a second therapeutic agent that forms a multiple drug system; (e) an agent that enhances the activity of the therapeutic agent or modified therapeutic agent; (f) at least one survivin modulator or inhibitor; (g) at least one multidrug resistance reversal agent; (h) at least one directed antibody conjugate; (i) at least one adjuvant; or (j) an additional therapeutic agent suitable for use with the therapeutic agent in a combinatorial regime, wherein the quantities of the therapeutic agent and the additional therapeutic agent are chosen to provide effective activity of both the therapeutic agent and the additional therapeutic agent; wherein the therapeutic agent or the modified therapeutic agent in the composition possesses increased therapeutic efficacy or reduced side effects as compared with the therapeutic agent or unmodified therapeutic agent as administered individually and not in the composition, wherein the unmodified therapeutic agent is bisantrene or a derivative or analog of bisantrene, and the modified therapeutic agent is a modification of bisantrene or a derivative or analog of bisantrene.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.31579
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15979041', '14907728', '14907729', '13817096', '14250958']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.774906247849747
- 35 USC 102 Novelty (BERT): 0.5311012459221314
- Combined Prediction Score: 0.7505257476569854
- Mean Citation Score: 276.52593
- Max Citation Score: 362.98706
- Similarity Product: 269.4838400312388

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test